Low dose radiation therapy for COVID-19: Effective dose and estimation of cancer risk.
Low dose radiation therapy for COVID-19: Effective dose and estimation of cancer risk.
复制标题
DOI：
10.1016/j.radonc.2020.09.051
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Sánchez-Nieto B
中科院分区：
文献类型：
--
作者：
García-Hernández T;Romero-Expósito M;Sánchez-Nieto B
新冠肺炎放射治疗年轻女性患癌症的风险是年轻男性的3倍。乳房和肺部是女性新冠肺炎放射治疗风险的主要贡献者。新冠肺炎放射治疗对野外器官的风险可以忽略不计。对于80岁以上的患者来说，新冠肺炎放射治疗的风险低于1%。新冠肺炎放射治疗的ED可与高暴露IR技术相媲美。本工作的目的是通过估计新冠肺炎感染后免疫相关肺炎的有效剂量和癌症的终生归因风险，来评估低剂量电离辐射治疗的致癌风险。LDRT治疗计划在男性和女性计算模体中进行。使用治疗计划系统计算和外周剂量模型(基于电离室测量)估计器官中的等量剂量。皮肤剂量用放射变色胶片估算。随后，根据放射防护程序计算有效剂量和LAR。每单位处方剂量对器官的当量剂量范围从10百万毫希/立方米到0.0051毫希/立方米。有效剂量从204毫希到426毫希不等，处方剂量从50毫希到100毫希不等。处方剂量为50cGy时，男性的总LAR为1.7%至0.29%，女性为4.9%至0.54%，年龄从20岁至80岁。导致风险的主要器官是肺和乳房。场外器官的风险很低，每10000人中不到0.06例。女性的LAR平均是同龄男性的2.2倍。有效剂量与高剂量介入放射学技术具有相同的数量级。对于60岁的男性来说，LAR是心脏CT的8倍，当处方剂量为50cGy时。
COVID-19 radiotherapy cancer risk for a young woman is 3 times that for a young man. Breast and lung are the main contributors to women’s risk from COVID-19 Radiotherapy. Risk for out-of-field organs is negligible for COVID-19 Radiotherapy. For 80 year-old patients, risk is lower than 1% for COVID-19 Radiotherapy. ED for COVID-19 Radiotherapy is comparable to higher exposure IR techniques. The objective of this work is to evaluate the risk of carcinogenesis of low dose ionizing radiation therapy (LDRT), for treatment of immune-related pneumonia following COVID-19 infection, through the estimation of effective dose and the lifetime attributable risk of cancer (LAR). LDRT treatment was planned in male and female computational phantoms. Equivalent doses in organs were estimated using both treatment planning system calculations and a peripheral dose model (based on ionization chamber measurements). Skin dose was estimated using radiochromic films. Later, effective dose and LAR were calculated following radiation protection procedures. Equivalent doses to organs per unit of prescription dose range from 10 mSv/cGy to 0.0051 mSv/cGy. Effective doses range from 204 mSv to 426 mSv, for prescription doses ranging from 50 cGy to 100 cGy. Total LAR for a prescription dose of 50 cGy ranges from 1.7 to 0.29% for male and from 4.9 to 0.54% for female, for ages ranging from 20 to 80 years old. The organs that mainly contribute to risk are lung and breast. Risk for out-of-field organs is low, less than 0.06 cases per 10000. Female LAR is on average 2.2 times that of a male of the same age. Effective doses are of the same order of magnitude as the higher-dose interventional radiology techniques. For a 60 year-old male, LAR is 8 times that from a cardiac CT, when prescription dose is 50 cGy.
登录
查看更多内容
DOI：
10.4103/0971-5916.174563
发表时间：
2015-12
期刊：
The Indian journal of medical research
影响因子：
--
作者：
Kaushik A;Jaimini A;Tripathi M;D'Souza M;Sharma R;Mondal A;Mishra AK;Dwarakanath BS
通讯作者：
Dwarakanath BS
影响因子：
3.8
作者：
Haelga, Roger A.;Besserer, Juergen;Schneider, Uwe
通讯作者：
Schneider, Uwe
影响因子：
3.8
作者：
Giaddui, Tawfik;Cui, Yunfeng;Xiao, Ying
通讯作者：
Xiao, Ying
DOI：
10.1016/j.ijrobp.2007.08.062
发表时间：
2008-01-01
影响因子：
7
作者：
Kan, Monica W. K.;Leung, Lucullus H. T.;Lam, Nelson
通讯作者：
Lam, Nelson
影响因子：
1
作者：
Nasab, Seyed Mohammad Bagher Hosseini;Deevband, Mohammad Reza;Feyzabad, Seyed Hasan Fatehi
通讯作者：
Feyzabad, Seyed Hasan Fatehi